 | Up a level |
Ruggeri, M; Pagan, E; Bagnardi, V; Bianco, N; Gallerani, E; Buser, K; Giordano, M; Gianni, L; Rabaglio, Manuela; Freschi, A; Cretella, E; Clerico, M; Farolfi, A; Simoncini, E; Ciccarese, M; Rauch, D; Ramello, M; Glaus, A; Berardi, R; Pellanda, A Franzetti; ... (2019). Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers. The breast, 47, pp. 85-92. Elsevier 10.1016/j.breast.2019.07.001
Francis, PA; Pagani, O; Fleming, GF; Walley, BA; Colleoni, M; Láng, I; Gómez, HL; Tondini, C; Ciruelos, E; Burstein, HJ; Bonnefoi, HR; Bellet, M; Martino, S; Geyer, Jr. CE; Goetz, MP; Stearns, V; Pinotti, G; Puglisi, F; Spazzapan, S; Climent, MA; ... (2018). Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England journal of medicine NEJM, 379(2), pp. 122-137. Massachusetts Medical Society MMS 10.1056/NEJMoa1803164
Gennari, A; Sun, Z; Hasler-Strub, U; Colleoni, M; Kennedy, M J; Von Moos, R; Cortés, J; Vidal, M J; Hennessy, B; Walshe, J; Amillano Parraga, K; Ribi, K; Bernhard, Jürg; Morales, S Murillo; Pagani, O; Barbeaux, A; Borstnar, S; Rabaglio, Manuela; Maibach, R; Regan, M M; ... (2018). A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. Annals of oncology, 29(3), pp. 661-668. Oxford University Press 10.1093/annonc/mdx772
Pagani, O; Klingbiel, D; Ruhstaller, T; Nolè, F; Eppenberger, S; Oehlschlegel, C; Bernhard, Jürg; Brauchli, P; Hess, D; Mamot, C; Munzone, E; Pestalozzi, B; Rabaglio, Manuela; Aebi, S; Ribi, K; Rochlitz, C; Rothgiesser, K; Thürlimann, B; von Moos, R; Zaman, K; ... (2017). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Annals of oncology, 28(2), pp. 305-312. Oxford University Press 10.1093/annonc/mdw622
Ribi, K; Aldridge, J; Phillips, K-A; Thompson, A; Harvey, V; Thürlimann, B; Cardoso, F; Pagani, O; Coates, A S; Goldhirsch, A; Price, K N; Gelber, R D; Bernhard, J (2012). Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. British journal of cancer, 106(10), pp. 1618-1625. Basingstoke: Nature Publishing Group 10.1038/bjc.2012.156
Zaman, K; Thürlimann, B; Huober, J; Schönenberger, A; Pagani, O; Lüthi, J; Simcock, M; Giobbie-Hurder, A; Berthod, G; Genton, C; Brauchli, P; Aebi, S (2012). Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Annals of oncology, 23(6), pp. 1474-1481. Oxford University Press 10.1093/annonc/mdr448
Keshaviah, A; Dellapasqua, S; Rotmensz, N; Lindtner, J; Crivellari, D; Collins, J; Colleoni, M; Thürlimann, B; Mendiola, C; Aebi, S; Price, K N; Pagani, O; Simoncini, E; Castiglione Gertsch, M; Gelber, R D; Coates, A S; Goldhirsch, A (2007). CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Annals of oncology, 18(4), pp. 701-8. Oxford: Oxford University Press 10.1093/annonc/mdl492
Hess, D; Koberle, D; Thurlimann, B; Pagani, O; Schonenberger, A; Mattmann, S; Rochlitz, C; Rauch, D; Schuller, J C; Ballabeni, P; Ribi, K (2007). Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). Onkologie, 73(3-4), pp. 228-37. Basel: Karger 10.1159/000180915
Pestalozzi, BC; Zahrieh, D; Price, KN; Holmberg, SB; Lindtner, J; Collins, J; Crivellari, D; Fey, MF; Murray, E; Pagani, O; Simoncini, E; Castiglione-Gertsch, M; Gelber, RD; Coates, AS; Goldhirsch, A; International, Breast Cancer Study Group (IBCSG) (2006). Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Annals of oncology, 17(6), pp. 935-44. Oxford: Oxford University Press 10.1093/annonc/mdl064
